scbmtБИОМЕДИЦИНАJournal Biomed2074-59822713-0428Scientific center of biomedical technologies of Federal Medical and Biological Agencyscbmt-1097Research ArticleСтатьиВлияние современных макролидов на смертность и зону некроза при моделировании острого коронароокклюзионного инфаркта миокардаЧерноморцеваЕ. С.noemail@neicon.ruГасановМ. Т.noemail@neicon.ruПокровскийМ. В.noemail@neicon.ruПокровскаяТ. Г.noemail@neicon.ruКочкаровВ. И.noemail@neicon.ruАртюшковаЕ. Б.noemail@neicon.ruСтепинаИ. В.noemail@neicon.ruКурский государственный медицинский университет, г. КурскRussian Federation20061302202014119121Copyright © Черноморцева Е.С., Гасанов М.Т., Покровский М.В., Покровская Т.Г., Кочкаров В.И., Артюшкова Е.Б., Степина И.В., 20202020Черноморцева Е.С., Гасанов М.Т., Покровский М.В., Покровская Т.Г., Кочкаров В.И., Артюшкова Е.Б., Степина И.В.Черноморцева Е.С., Гасанов М.Т., Покровский М.В., Покровская Т.Г., Кочкаров В.И., Артюшкова Е.Б., Степина И.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.scbmt.ru/jour/article/view/1097азитромицинрокситромицинкларитромицинмидекамицинджозамицининфаркт миокардаReferencesCarevic O. Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes. /O. Carevic // Agents Actions. − 1988. Aug; 25 (1-2). P. 124-131.Carevic O. Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes. /O. Carevic // Agents Actions. − 1988. Aug; 25 (1-2). P. 124-131.Cercek B, Shah PK, Noc M, et al. The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndromes. Lancet 2001;361:809-13.Cercek B, Shah PK, Noc M, et al. The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndromes. Lancet 2001;361:809-13.Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999;20:121-7.Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999;20:121-7.Lambro MT, El Benna J, Babin-Chevaye´C. Comparison of the in vitro effect of several macrolides on the oxidative burst of human neutrophil. J Antimicrob Chemother 1989; 24: 561-572.Lambro MT, El Benna J, Babin-Chevaye´C. Comparison of the in vitro effect of several macrolides on the oxidative burst of human neutrophil. J Antimicrob Chemother 1989; 24: 561-572.Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000;102:1755-60. 6. O'Connor MC, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary artery disease events. The WIZARD study: a randomized controlled trial. JAMA 2003;290:1459-66.Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000;102:1755-60. 6. O'Connor MC, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary artery disease events. The WIZARD study: a randomized controlled trial. JAMA 2003;290:1459-66.
The authors declare that there are no conflicts of interest present.